Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 9, 2012 David Williamson	Inhibitex Is an Instant Double Some takeout rumors do come true.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool January 10, 2012 Sean Williams	Idenix Pharmaceuticals Shares Skyrocketed Again: What You Need to Know Shares of hepatitis-C drug hopeful Idenix Pharmaceuticals are continuing their rally for a second day, currently up 21%, as speculation swirls that it will be the next takeover candidate.
The Motley Fool November 30, 2011 Brian Orelli	Up Big With Room to Run Lofty hep C valuations are par for the course.
The Motley Fool November 5, 2011 David Williamson	Inhibitex Investors: Why Shares Popped 115% Great results for INX-189 send shares skyward.
The Motley Fool November 21, 2011 David Williamson	Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved.
The Motley Fool January 9, 2012 Brian Orelli	3 Reasons Hep C Premiums Might Not Last Careful what you wish for.
The Motley Fool November 29, 2011 Brian Orelli	Every Biotech Is for Sale It just depends on the right price.
The Motley Fool September 7, 2010 Luke Timmerman	ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C.
Chemistry World January 11, 2012 Andrew Turley	BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection.
The Motley Fool October 8, 2010 Luke Timmerman	Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool November 1, 2004 Brian Gorman	Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes.
The Motley Fool April 29, 2004 Bill Mann	Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
BusinessWeek February 26, 2007 Arlene Weintraub	The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target.
The Motley Fool April 28, 2011 Brian Orelli	1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix.
BusinessWeek January 29, 2007 Arlene Weintraub	More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl.
The Motley Fool November 7, 2011 David Williamson	Health-Care News You Can't Afford to Miss Highlighting the day's health-care stories: FDA approval for Johnson & Johnson... Inhibitex kept its streak of double-digit gains alive with another 14% surge today... 13% plunge for Optimer Pharmaceuticals...
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool November 30, 2011 David Williamson	5 Top November Health-Care Stocks These stocks had an amazing month.
The Motley Fool January 29, 2007 Brian Lawler	Bristol-Myers Blames the Generic Again The fourth quarter's financial results are dominated by generic competition.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool December 28, 2011 Sean Williams	My Top 10 CEOs of 2011: Part 2 Santa Claus delivers year-round for these shareholders, thanks to these CEOs.
Chemistry World October 26, 2012 Andrew Turley	Patent woes lead to sharp sales losses Financial results for the third quarter of 2012 from several big pharma companies reveal a dramatic loss of sales as patent protection for key drugs expires. It is an all too familiar story for the industry
The Motley Fool December 16, 2011 Brian Orelli	Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function.
The Motley Fool July 30, 2007 Brian Lawler	Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better.
The Motley Fool January 19, 2012 Brian Orelli	New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go.
The Motley Fool January 27, 2005 Stephen D. Simpson	Generics Bout Gets Bloody Bristol-Myers Squibb struggles to keep growing amid patent expirations.
The Motley Fool July 13, 2011 David Williamson	Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool October 26, 2007 Billy Fisher	A Quarter to Boast About at Bristol Bristol-Myers announces a 22% rise in third-quarter revenue as Plavix sales continue to rise. Investors, take note.
The Motley Fool July 29, 2004 Brian Gorman	Bristol-Myers Bottoming Out? The pharmaceutical company's expectations are in doubt, but investors might want to focus on its potential.
The Motley Fool September 11, 2007 Brian Lawler	Score One for Pharmasset Shares of Pharmasset were up after the company announced impressive results for its Hepatitis C virus drug candidate R7128. Investors should continue to watch closely.
The Motley Fool December 18, 2007 Brian Orelli	Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month.
The Motley Fool April 27, 2006 Stephen D. Simpson	A Sluggish Bristol-Myers Squibb Generic erosion is going to chew away revenue and profits. Investors, at today's prices, there are just too many other better ideas to go after.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
Fast Company March 2015 J.J. McCorvey	How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone.
The Motley Fool October 28, 2005 Stephen D. Simpson	Bristol-Myers' Bad Mojo The possible loss of the experimental diabetes drug Pargluva is a blow to this pharmaceutical that's already hurting for growth. If you're expecting a near-term bang for your investment buck, this might not be the best destination.
The Motley Fool June 12, 2008 Brian Lawler	Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
BusinessWeek October 17, 2005 Amy Barrett	Prescription For Upheaval How the Medicare drug program is tightening the screws on Big Pharma.
The Motley Fool October 26, 2010 Brian Orelli	Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs.
The Motley Fool June 3, 2011 Brian Orelli	Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up.
The Motley Fool September 13, 2006 Brian Lawler	What to Make of Bristol-Myers Take a good look at the industry to try to sort out the meaning of all the news and the rumors. Investing in a company based on a possible buyout is never a good idea when the possibility is based solely on rumors and analyst speculation.
The Motley Fool April 28, 2008 Brian Lawler	Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results.
The Motley Fool January 9, 2012 Travis Hoium	Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug.
The Motley Fool October 30, 2006 Brian Lawler	Sales Slow Down for Bristol-Myers Plavix isn't the only drug facing a challenging future. Losing patent protection and facing generic competition can be disastrous to sales and earnings if a pharmaceutical company doesn't have a way to drive revenue growth. Investors, take note.
The Motley Fool May 1, 2007 Brian Lawler	Bristol-Myers Stops Spinning in Place Bristol-Myers releases first-quarter financial results. Investors, take note.